Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,432 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,449 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05003856 | Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule | terminated | N/A | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05126797 | 3D Printed Oral Stents for Patients With Head and Neck Cancer Receiving Radiation Therapy | terminated | N/A | 57 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT00448240 |
| Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer |
| terminated |
| Phase 2 / Phase 3 |
| 6 |
| Henry Ford Health SystemOTHER |
| 0 |
| Mar 18, 2025 |
| clinicaltrials |
| NCT02827838 | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | terminated | Early Phase 1 | 17 | Wake Forest University Health SciencesOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC | terminated | Phase 1 | 26 | Viracta Therapeutics, Inc.INDUSTRY | 8 | Mar 12, 2025 | clinicaltrials |
| NCT03727061 | Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer | terminated | Phase 1 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | terminated | Phase 2 | 205 | Seagen Inc.INDUSTRY | 6 | Mar 10, 2025 | clinicaltrials |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | terminated | Phase 1 | 31 | Turnstone Biologics, Corp.INDUSTRY | 2 | Mar 10, 2025 | clinicaltrials |
| NCT04465487 | Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | terminated | Phase 1 | 38 | Regeneron PharmaceuticalsINDUSTRY | 2 | Feb 24, 2025 | clinicaltrials |
| NCT04502888 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | terminated | Phase 1 | 5 | Shattuck Labs, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | terminated | Phase 1 | 40 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06054477 | Study of ALE.C04 in Patients With Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 21 | Alentis Therapeutics AGINDUSTRY | 8 | Feb 17, 2025 | clinicaltrials |
| NCT04588038 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery | terminated | Phase 1 | 4 | Hyunseok Kang, MDOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04162873 | Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer | terminated | Phase 2 | 13 | University of UtahOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT03461354 | MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer | terminated | N/A | 49 | Wake Forest University Health SciencesOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT05457478 | The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients With Head and Neck Cancer Undergoing Radiation Therapy | terminated | N/A | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT04658342 | Effects of Oral Cancer Treatments on Upper Esophageal Opening During Swallowing | terminated | — | 5 | University of Wisconsin, MadisonOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04217057 | Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer | terminated | Phase 1 | 11 | Washington University School of MedicineOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03539198 | Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer | terminated | — | 19 | Mayo ClinicOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | terminated | Phase 1 / Phase 2 | 12 | Atara BiotherapeuticsINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT04220775 | Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04795713 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | terminated | Phase 1 | 64 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05265013 | ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases | terminated | Phase 2 | 16 | Rakuten Medical, Inc.INDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03153982 | Ruxolitinib in Operable Head and Neck Cancer | terminated | Phase 2 | 16 | University of California, San FranciscoOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT03452137 | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck(IMvoke010) | terminated | Phase 3 | 406 | Hoffmann-La RocheINDUSTRY | 23 | Oct 9, 2024 | clinicaltrials |
| NCT01284348 | To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 26 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 29, 2024 | clinicaltrials |
| NCT02875613 | Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer | terminated | Phase 2 | 6 | Assuntina Sacco, M.D.OTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT05153733 | Improved Implant for Reconstruction Purposes After Mandibular Resection(RifRam) | terminated | N/A | 3 | The Netherlands Cancer InstituteOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05328076 | Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography(ANGIO_PARA) | terminated | — | 22 | IRCCS San RaffaeleOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | terminated | Phase 1 / Phase 2 | 41 | Turning Point Therapeutics, Inc.INDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | terminated | Phase 2 | 9 | University of ArizonaOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04659369 | Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC | terminated | Phase 1 | 21 | Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04936841 | Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03602066 | Study Evaluating The Role of ClO2 on Mucositis for Pt. Undergoing Head/Neck Radiotherapy | terminated | Phase 2 | 14 | University of ArizonaOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06189482 | Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma(NPC) | terminated | N/A | 56 | Zeng ChanghaoOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | terminated | Phase 1 | 35 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06248840 | Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma | terminated | N/A | 56 | Zeng ChanghaoOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03403361 | Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of Patients Treated With Proton or Photon Therapy | terminated | N/A | 36 | Washington University School of MedicineOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04624113 | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | terminated | Phase 1 | 13 | Washington University School of MedicineOTHER | 1 | Feb 21, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2025source: clinicaltrials